These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 21551089)

  • 21. Mortality in chronic kidney disease and mineral metabolism.
    Floege J; Kronenberg F; Froissart M
    JAMA; 2011 Jul; 306(2):159; author reply 159-60. PubMed ID: 21750291
    [No Abstract]   [Full Text] [Related]  

  • 22. Emerging roles of cinacalcet hydrochloride in the management of CKD-MBD.
    Fukagawa M; Suzuki M
    Ther Apher Dial; 2009 Oct; 13 Suppl 1():S1. PubMed ID: 19765251
    [No Abstract]   [Full Text] [Related]  

  • 23. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease.
    Rouached M; El Kadiri Boutchich S; Al Rifai AM; Garabédian M; Fournier A
    Kidney Int; 2008 Aug; 74(3):389-90. PubMed ID: 18626497
    [No Abstract]   [Full Text] [Related]  

  • 24. [Chronic kidney disease and nutrition].
    Yoshida T; Kumagai H
    Clin Calcium; 2016 Mar; 26(3):369-74. PubMed ID: 26923973
    [TBL] [Abstract][Full Text] [Related]  

  • 25. How many measurements to make a decision?
    Houillier P; Coste J; Froissart M
    Clin J Am Soc Nephrol; 2010 Jul; 5(7):1161-2. PubMed ID: 20558565
    [No Abstract]   [Full Text] [Related]  

  • 26. Plasma parathyroid hormone level and prevalent cardiovascular disease in CKD stages 3 and 4: an analysis from the Kidney Early Evaluation Program (KEEP).
    Bhuriya R; Li S; Chen SC; McCullough PA; Bakris GL
    Am J Kidney Dis; 2009 Apr; 53(4 Suppl 4):S3-10. PubMed ID: 19285609
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Parathyroid function after kidney allografting.
    Tajima A; Ishikawa A; Ohta N; Suzuki K; Kawabe K; Aso Y
    Transplant Proc; 1996 Jun; 28(3):1629-30. PubMed ID: 8658814
    [No Abstract]   [Full Text] [Related]  

  • 28. Target levels for serum phosphorus and parathyroid hormone.
    Qunibi W; Kalantar-Zadeh K
    Semin Dial; 2011; 24(1):29-33. PubMed ID: 21324001
    [No Abstract]   [Full Text] [Related]  

  • 29. Paricalcitol as compared with calcitriol in patients undergoing hemodialysis.
    Drüeke TB; McCarron DA
    N Engl J Med; 2003 Jul; 349(5):496-9. PubMed ID: 12890849
    [No Abstract]   [Full Text] [Related]  

  • 30. Japanese Society of Dialysis Therapy treatment guidelines for secondary hyperparathyroidism.
    Kazama JJ
    Ther Apher Dial; 2007 Oct; 11 Suppl 1():S44-7. PubMed ID: 17976085
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS).
    Tentori F; Blayney MJ; Albert JM; Gillespie BW; Kerr PG; Bommer J; Young EW; Akizawa T; Akiba T; Pisoni RL; Robinson BM; Port FK
    Am J Kidney Dis; 2008 Sep; 52(3):519-30. PubMed ID: 18514987
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Phosphorus and calcium metabolism and its hormonal regulation in chronic kidney failure].
    Nikiforova NV; Strunin SE; Ermolenko VM; Mozzhechkov VT; Khomiakova VN
    Ter Arkh; 1985; 57(1):103-7. PubMed ID: 3983831
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Changes in parathyroid hormone, body mass index and the association with mortality in dialysis patients.
    Drechsler C; Grootendorst DC; Boeschoten EW; Krediet RT; Wanner C; Dekker FW;
    Nephrol Dial Transplant; 2011 Apr; 26(4):1340-6. PubMed ID: 20841493
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Paricalcitol, calcitriol, and survival of patients undergoing hemodialysis.
    Colussi G
    N Engl J Med; 2003 Nov; 349(20):1971-2; author reply 1971-2. PubMed ID: 14614175
    [No Abstract]   [Full Text] [Related]  

  • 35. Mineral metabolism management in hemodialysis patients with secondary hyperparathyroidism in Japan: baseline data from the MBD-5D.
    Fukagawa M; Komaba H; Onishi Y; Fukuhara S; Akizawa T; Kurokawa K;
    Am J Nephrol; 2011; 33(5):427-37. PubMed ID: 21508631
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mineral metabolism disorders in chronic kidney disease.
    Kestenbaum B
    JAMA; 2011 Mar; 305(11):1138-9. PubMed ID: 21406655
    [No Abstract]   [Full Text] [Related]  

  • 37. [The metabolism of calcium and phosphorus in diabetic nephropathies].
    Taboga C; Bertolissi F; Benedetti A
    Minerva Nefrol; 1982; 29(3 Suppl):29-35. PubMed ID: 7145220
    [No Abstract]   [Full Text] [Related]  

  • 38. Paricalcitol, calcitriol, and survival of patients undergoing hemodialysis.
    Kida Y
    N Engl J Med; 2003 Nov; 349(20):1971-2; author reply 1971-2. PubMed ID: 14626256
    [No Abstract]   [Full Text] [Related]  

  • 39. Is there an association between elevated or low serum levels of phosphorus, parathyroid hormone, and calcium and mortality in patients with end stage renal disease? A meta-analysis.
    Natoli JL; Boer R; Nathanson BH; Miller RM; Chiroli S; Goodman WG; Belozeroff V
    BMC Nephrol; 2013 Apr; 14():88. PubMed ID: 23594621
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness of phosphate binders in adult patients with end stage renal disease receiving hemodialysis: a systematic review protocol.
    Gasu V; Ashong M; Seferi A; Fitzpatrick A
    JBI Database System Rev Implement Rep; 2018 Apr; 16(4):838-844. PubMed ID: 29634508
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.